Treatment Of Adult Patients With Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Advanced Or Metastatic Breast Cancer In Combination With Fulvestrant In Patients With Disease Progression Following Endocrine Therapy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for treatment of adult patients with hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy. 30 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
30
Active US patents
43/100
Avg vulnerability
—
Annual revenue covered

Originators in Treatment Of Adult Patients With Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Advanced Or Metastatic Breast Cancer In Combination With Fulvestrant In Patients With Disease Progression Following Endocrine Therapy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 30 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating treatment of adult patients with hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy. Each bar = one year. Y-axis scaled to peak year (12 patents).

12
27
12
34
3
36
3
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Palbociclib
palbociclib
 Pfizer Inc. 30 43 — 2027-03-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE47739 Palbociclib other 75 2027-09-05
RE47739 Palbociclib other 75 2027-09-05
RE47739 Palbociclib other 75 2027-09-05
RE47739 Palbociclib other 75 2027-09-05
RE47739 Palbociclib other 75 2027-09-05
RE47739 Palbociclib other 75 2027-09-05
10723730 Palbociclib other 62 2034-08-08
10723730 Palbociclib other 62 2034-08-08
10723730 Palbociclib other 62 2034-08-08
10723730 Palbociclib other 62 2034-08-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10723730 Palbociclib composition of matter 4 2034-02-08
10723730 Palbociclib composition of matter 4 2034-02-08
10723730 Palbociclib composition of matter 4 2034-02-08
10723730 Palbociclib composition of matter 4 2034-02-08
10723730 Palbociclib composition of matter 4 2034-02-08
10723730 Palbociclib composition of matter 4 2034-02-08
RE47739 Palbociclib composition of matter 22 2027-03-05
RE47739 Palbociclib composition of matter 22 2027-03-05
RE47739 Palbociclib composition of matter 22 2027-03-05
RE47739 Palbociclib composition of matter 22 2027-03-05

Related